Capricor Therapeutics (CAPR) announced the commencement of a proposed underwritten public offering of shares of its common stock. The company intends to use the net proceeds from the proposed offering for the continued development of its product candidates, manufacturing of its product candidates, working capital and general corporate purposes. Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the proposed public offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics price target raised to $50 from $25 at Maxim
- Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
- Capricor Therapeutics price target raised to $48 from $16 at Alliance Global
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Capricor Therapeutics price target raised to $60 from $24 at H.C. Wainwright